Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Pieter SonneveldAsher Chanan-KhanKatja WeiselAjay K NookaTamas MassziMeral BeksacIvan SpickaVania Tietsche de Moraes HungriaMarkus MunderMaria-Victoria Mateos-MantecaTomer M MarkMark-David LevinTahamtan AhmadiXiang QinWendy Garvin MayoXue GaiJodi CareyRobin CarsonAndrew SpencerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).